Monarch Casino & Resort received a reiterated Buy rating due to strong EBITDA and free cash flow from its Atlantis and Black Hawk properties. Analyst Pedro Goulart highlights a 20% upside target of $147 per share, supported by Reno's tourism momentum and infrastructure improvements, as well as robust growth in Black Hawk. Discounted cash flow models justify a valuation range of $136–$149 per share, indicating the stock is slightly undervalued with positive catalysts ahead. This outlook aligns with Texas Capital's recent Buy initiation and long-term valuation expectations.
Monarch Casino & Resort is the subject of recent analyst attention with a reiterated Buy rating and a 20% upside target. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 28, 2026 23:31 WIB: of 112 priced US stocks, 57 rose and 53 fell. Notable movers include CVNA at USD 60.45 with a -7.09% change, RENT at USD 1.56 with a -6.59% change, and QS at USD 4.62 with a -5.91% change.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
Shareholders of Silver Hammer Mining Corp., Stroud Resources Ltd., and SilverMark Resources Inc. have overwhelmingly approved their amalgamation to create Silver Frontier Resources Corp. This merger combines their silver assets and expertise to build...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
